Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity

Yasmina Mozo(Hospital Universitario La Paz), Beatriz Ruz-Caracuel(Hospital La Paz Institute for Health Research), Juan Manuel Torres(Hospital La Paz Institute for Health Research), David Bueno(Hospital Universitario La Paz), Alba Fernández‐Arroyo(Hospital Universitario La Paz), Cristina Ferreras(King's College London), Adela Escudero(Hospital Clínico San Carlos), Antonio Pérez‐Martínez(Hospital Universitario La Paz), Blanca Rosich(Hospital Universitario La Paz), María Luz Uria Oficialdegui(Vall d'Hebron Hospital Universitari), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Luisa Sisinni(Hospital de Sant Pau), Laura Alonso(Vall d'Hebron Hospital Universitari), Carmen Mestre‐Durán(Hospital La Paz Institute for Health Research), Itsaso Losantos(Hospital Universitario La Paz), María Isabel Benítez‐Carabante
Pediatric Hematology and Oncology
March 4, 2021
Cited by 28


Related Papers